Gilead stock is closely tied to its HIV treatments. But with Biktarvy's patent expirations looming, can the giant survive?

In the latest close session, Gilead Sciences (GILD) was down 1.48% at $134.28. This change lagged the S&P 500's daily loss of ...

Gilead's expansion beyond HIV therapies will surprise many investors.

Assembly Biosciences has evolved into a strategically financed antiviral platform, underpinned by a robust partnership with Gilead. Learn why ASMB stock is a buy.

July 14 (Reuters) - Researchers in the Democratic Republic of Congo said on Tuesday they have started enrolling participants ...

In the latest close session, Gilead Sciences (GILD) was down 3.72% at $129.83. The stock's performance was behind the S&P 500 ...

A group of AIDS activists obtained an R&D pact at the heart of a settlement between the U.S. government and Gilead Sciences ...

Gilead Sciences’ Up To Date campaign with comedians Nicole Byer and Devon Walker hopes to normalize conversations about HIV prevention, testing and PrEP. The campaign targets Black women through ...

Despite a recent FDA clinical hold on its HIV treatment trials (GS-1720 and GS-4182) due to a decrease in CD4+ T-cells, Gilead Sciences (NASDAQ:GILD) has shown strong performance this year. Its stock ...

Gilead Sciences has developed an industry-leading HIV portfolio in recent years with its megablockbuster daily treatment Biktarvy and its new long-acting pre-exposure prophylaxis (PrEP) medicine ...

Shares of Gilead Sciences Inc. GILD advanced 5.21% to $136.36 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.45% to ...

Making a creative pharma campaign that earns recognition at the prestigious Cannes Lions Festival of Creativity is a beast. Gilead Sciences conquered the task with the help of some AI-generated ...